BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Crespo-Facorro B, Ruiz-Veguilla M, Vázquez-Bourgon J, Sánchez-Hidalgo AC, Garrido-Torres N, Cisneros JM, Prieto C, Sainz J. Aripiprazole as a Candidate Treatment of COVID-19 Identified Through Genomic Analysis. Front Pharmacol 2021;12:646701. [PMID: 33762960 DOI: 10.3389/fphar.2021.646701] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Canal-Rivero M, Vázquez-Hernández J, León-Gómez M, Maraver-Ayala S, Fernández-Portes L, Sánhez-Benítez S, Garrido-Torres N, Ruiz-Veguilla M, Crespo-Facorro B. Epidemiology of infection, transmission and COVID-19 outcomes among mental health users and workers in a comprehensive network of long-term mental health facilities: Retrospective observational population-base study. Schizophr Res 2023;254:1-7. [PMID: 36736100 DOI: 10.1016/j.schres.2023.01.020] [Reference Citation Analysis]
2 Gardinassi LG, Souza COS, de Lima DV, Sales-campos H, da Fonseca SG. Transcriptomic approaches in COVID-19: From infection to vaccines. Omics Approaches and Technologies in COVID-19 2023. [DOI: 10.1016/b978-0-323-91794-0.00003-2] [Reference Citation Analysis]
3 Fico G, Isayeva U, De Prisco M, Oliva V, Solè B, Montejo L, Grande I, Arbelo N, Gomez-Ramiro M, Pintor L, Carpiniello B, Manchia M, Vieta E, Murru A. Psychotropic drug repurposing for COVID-19: A Systematic Review and Meta-Analysis. Eur Neuropsychopharmacol 2023;66:30-44. [PMID: 36399837 DOI: 10.1016/j.euroneuro.2022.10.004] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Strawbridge R, Izurieta E, Day E, Tee H, Young K, Tong CC, Young AH, Cleare AJ. Peripheral inflammatory effects of different interventions for treatment-resistant depression: A systematic review. Neuroscience Applied 2022. [DOI: 10.1016/j.nsa.2022.101014] [Reference Citation Analysis]
5 Liberman JN, Pesa J, Petrillo MP, Ruetsch C. Factors associated with COVID-19 Infection among a national population of individuals with schizophrenia or schizoaffective disorder in the United States. BMC Psychiatry 2022;22. [DOI: 10.1186/s12888-022-04026-7] [Reference Citation Analysis]
6 Tang SW, Leonard BE, Helmeste DM. Long COVID, neuropsychiatric disorders, psychotropics, present and future. Acta Neuropsychiatr 2022;34:109-26. [PMID: 35144718 DOI: 10.1017/neu.2022.6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
7 May M, Barlow D, Ibrahim R, Houseknecht KL. Mechanisms Underlying Antipsychotic-Induced NAFLD and Iron Dysregulation: A Multi-Omic Approach. Biomedicines 2022;10:1225. [DOI: 10.3390/biomedicines10061225] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Costanza A, Amerio A, Aguglia A, Serafini G, Amore M, Hasler R, Ambrosetti J, Bondolfi G, Sampogna G, Berardelli I, Fiorillo A, Pompili M, Nguyen KD. Hyper/neuroinflammation in COVID-19 and suicide etiopathogenesis: Hypothesis for a nefarious collision? Neurosci Biobehav Rev 2022;136:104606. [PMID: 35289272 DOI: 10.1016/j.neubiorev.2022.104606] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Mueller JK, Riederer P, Müller WE. Neuropsychiatric Drugs Against COVID-19: What is the Clinical Evidence? Pharmacopsychiatry 2022;55:7-15. [DOI: 10.1055/a-1717-2381] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
10 Hasankhani A, Bahrami A, Sheybani N, Aria B, Hemati B, Fatehi F, Ghaem Maghami Farahani H, Javanmard G, Rezaee M, Kastelic JP, Barkema HW. Differential Co-Expression Network Analysis Reveals Key Hub-High Traffic Genes as Potential Therapeutic Targets for COVID-19 Pandemic. Front Immunol 2021;12:789317. [PMID: 34975885 DOI: 10.3389/fimmu.2021.789317] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
11 Vai B, Mazza MG, Marisa CD, Beezhold J, Kärkkäinen H, Saunders J, Samochowiec J, Benedetti F, Leboyer M, Fusar-poli P, De Picker L. Joint European policy on the COVID-19 risks for people with mental disorders: An umbrella review and evidence- and consensus-based recommendations for mental and public health. Eur Psychiatr 2022;65:e47. [DOI: 10.1192/j.eurpsy.2022.2307] [Reference Citation Analysis]
12 Prokopez CR, Farinola R, Vallejos M, Lopredo LS, Sfriso LE, Chiapella LC, Arce C, Corral RM, Cuesta MJ, Alomo M. Olanzapine, risperidone and quetiapine: Do these atypical antipsychotics have a protective effect for SARS-CoV-2? Schizophrenia Research 2022. [DOI: 10.1016/j.schres.2022.01.035] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Sharma OP, Seiz W, Scheele J. SARS-CoV-2 Therapeutic Landscape, Opportunity and Future Threats. TOCOVIDJ 2021;1:205-215. [DOI: 10.2174/2666958702101010205] [Reference Citation Analysis]
14 Jesuthasan A, Massey F, Manji H, Zandi MS, Wiethoff S. Emerging potential mechanisms and predispositions to the neurological manifestations of COVID-19. J Neurol Sci 2021;428:117608. [PMID: 34391037 DOI: 10.1016/j.jns.2021.117608] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
15 Canal-Rivero M, Catalán-Barragán R, Rubio-García A, Garrido-Torres N, Crespo-Facorro B, Ruiz-Veguilla M; IBIS Translational Psychiatry Group. The role of antipsychotics against COVID-19: A topic for debate. Schizophr Res 2021;235:5-6. [PMID: 34274797 DOI: 10.1016/j.schres.2021.07.003] [Reference Citation Analysis]
16 Rivas-Ramírez ÁR, Tendilla-Beltrán H, Gómez-Mendoza LE, Loaiza G, Flores G. Patients with schizophrenia have decreased COVID-19 prevalence among hospitalised patients with psychiatric and neurological diseases: A retrospective analysis in Mexican population. Int J Clin Pract 2021;:e14528. [PMID: 34125988 DOI: 10.1111/ijcp.14528] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
17 Tendilla-Beltrán H, Flores G. Due to their anti-inflammatory, antioxidant and neurotrophic properties, second-generation antipsychotics are suitable in patients with schizophrenia and COVID-19. Gen Hosp Psychiatry 2021;71:137-9. [PMID: 34045093 DOI: 10.1016/j.genhosppsych.2021.05.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
18 Barh D, Aljabali AA, Tambuwala MM, Tiwari S, Serrano-Aroca Á, Alzahrani KJ, Silva Andrade B, Azevedo V, Ganguly NK, Lundstrom K. Predicting COVID-19-Comorbidity Pathway Crosstalk-Based Targets and Drugs: Towards Personalized COVID-19 Management. Biomedicines 2021;9:556. [PMID: 34067609 DOI: 10.3390/biomedicines9050556] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
19 Carro B. SARS-CoV-2 mechanisms of action and impact on human organism, risk factors and potential treatments. An exhaustive survey. All Life 2021;14:894-947. [DOI: 10.1080/26895293.2021.1977186] [Reference Citation Analysis]